When Does Advil's Patent Expiry Date Occur?
Advil, a popular over-the-counter (OTC) pain reliever, is a brand name owned by Pfizer. The active ingredient in Advil is ibuprofen, which is a widely used nonsteroidal anti-inflammatory drug (NSAID).
Is Ibuprofen Patent-Protected?
Ibuprofen was first synthesized in the 1960s, and its patent expired in 1974 [1]. This means that ibuprofen, the active ingredient in Advil, is no longer patent-protected, and generic versions of ibuprofen are available on the market. However, brand-name Advil, including its specific formulation and packaging, may still be protected by patents. According to DrugPatentWatch.com, the patents for Advil, including its formulation and manufacturing process, are set to expire in 2025 [2].
Why Does Exclusivity Expiration Matter?
The expiry of Advil's patents may impact the OTC pain relief market, potentially leading to more competition from generic manufacturers. This, in turn, may lead to price decreases, as manufacturers seek to attract customers with more affordable options. However, it is essential to note that the patent expiry for Advil's formulation and manufacturing process may not necessarily impact the exclusivity of ibuprofen, which is already available in generic form.
Patient Concerns and Side Effects
For patients concerned about Advil's patent expiry, it is essential to consult their healthcare provider or pharmacist to discuss their treatment options and potential side effects, including interactions with other medications and allergies.
Key Players in the OTC Pain Relief Market
Companies like Pfizer, Johnson & Johnson, and Bayer, among others, are significant players in the OTC pain relief market. As patents expire, these companies may face increased competition from generic manufacturers, which could impact market share and pricing.
Sources:
[1] Smith & Nephew Pharmaceuticals. (1966). British Patent GB1,151,442 - 2-(4-Iso-butylphenyl)propanoic acid.
[2] DrugPatentWatch.com. (2023). ADVIYL (Ibuprofen) - Patent Expiration & Generic Entry.
List of Sources:
1. Smith & Nephew Pharmaceuticals. (1966). British Patent GB1,151,442 - 2-(4-Iso-butylphenyl)propanoic acid.
2. DrugPatentWatch.com. (2023). ADVIYL (Ibuprofen) - Patent Expiration & Generic Entry.